Promising Results at 1 Year Follow-Up Following Familial Haploidentical (FHI) T-cell Depleted (TCD) With CD 34 Enrichment and T-cell (CD3) Addback Allogeneic Stem Cell Transplantation in Patients With High-Risk Sickle Cell Disease

Authors

J Talano
T Moore
C Keever-Taylor
S Shenoy
M Walters
S Parsons
Allen Dozor, New York Medical CollegeFollow
Deborah Friedman, New York Medical CollegeFollow
Qiuhu Shi, New York Medical CollegeFollow
S Braniecki
B Grossman
R Weinberg
E Vichinsky
Yaya Chu, New York Medical CollegeFollow
E Morris
S Fabricatore
J AyelloFollow
L Baxter-Lowe
Mitchell Cairo, New York Medical CollegeFollow

Document Type

Abstract

Publication Date

December 2017

Journal Title

Blood

Department

Medicine

Recommended Citation

Talano, J., Moore, T., Keever-Taylor, C., Shenoy, S., Walters, M., Parsons, S., Dozor, A., Friedman, D., Shi, Q., Braniecki, S., Grossman, B., Weinberg, R., Vichinsky, E., Chu, Y., Morris, E., Fabricatore, S., Ayello, J., Baxter-Lowe, L., & Cairo, M. (2017). Promising Results at 1 Year Follow-Up Following Familial Haploidentical (FHI) T-cell Depleted (TCD) With CD 34 Enrichment and T-cell (CD3) Addback Allogeneic Stem Cell Transplantation in Patients With High-Risk Sickle Cell Disease. Blood, 130 (Suppl. 1), 4602. Retrieved from https://touroscholar.touro.edu/nymc_fac_abstracts/146